ESC Congress 2022 Update by Macleods Pharma - Video

Topics Covered:
(1) 2022 ESC Guidelines on ventricular arrhythmias and sudden cardiac death
(2) 2022 ESC Guidelines on cardio-oncology
(3) 2022 ESC Guidelines on pulmonary hypertension
(4) 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(5) TIME - The Treatment in Morning versus Evening study
(6) A decade of innovation, guidelines and paradigm shifts in LDL-C management
(7)HOT LINE SESSION :Pooled analysis of DAPA-HF and DELIVER
(8)New strategies to manage AF
(9)Transcatheter tricuspid valve repair: techniques and results
(10 )Gender differences in treatment and outcome in arterial hypertension
(11)TAVI turned 20! A look back and a vision for the future
(12)How to treat a patient with heart failure and LVEF Less than 40%
(13)Beyond echo and MRI: what other imaging is useful in HFpEF
(14)Effects of dapagliflozin on cardiovascular and kidney events by baseline eGFR and UACR in patients with type 2 diabetes mellitus: A patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials
(15)PACIFIC-AMI - Efficacy and safety of factor XIa inhibitor asundexian on top of dual antiplatelet therapy after acute myocardial infarction
(16)Rivaroxban for Rheumatic Heart Disease associated atrial fibrillation - INVICTUS
(17) Relationship between endothelin-1, heart failure with reduced ejection fraction and dapagliflozin: findings from DAPA-HF
(18)Which drug when: how to sequence heart failure drugs in 2022
(19)AXIOMATIC-SSP: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention
(20)Oral anticoagulation in patients with atrial fibrillation and stage IV and V chronic kidney disease: a systematic review and meta-analysis
(21)SGLT-2 inhibitors - Another piece of the puzzle in heart failure
(22)PARADISE-MI Trial - Win Ratio Analysis
(23)How to achieve blood pressure targets in clinical practice
(24)15-month results of the MASTER DAPT trial
(25) ISCHEMIA-CKD EXTEND - Clinical Outcomes at 5 years of Follow-up
(26)Management of multivalvular disease in patients with severe aortic stenosis
(27) The management challenge of atrial fibrillation in HFrEF and HFpEF – discussion

Academic Partner : Macleods Pharma
Digital Partner : Carbon Brands Solutions